rs72547517 — CYP1A2 *8

CYP1A2*8 — near-complete loss-of-function missense variant causing severely reduced CYP1A2 enzyme activity; predominantly found in East Asian (Japanese) populations

See your personal result for CYP1A2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

CYP1A2*8 — Near-Complete Loss of Liver Enzyme Activity

CYP1A211 CYP1A2
Cytochrome P450 family 1 subfamily A member 2 — the liver enzyme that processes about 95% of caffeine and several widely prescribed medications is one of the most clinically relevant drug-metabolizing enzymes in the body. The CYP1A2*8 allele (rs72547517) is a missense variant that substitutes histidine for arginine at position 456 of the enzyme (p.Arg456His), crippling the enzyme's ability to fold around its heme cofactor and carry out oxidative metabolism. This allele is extremely rare in most global populations but occurs at measurable frequency in Japanese and broader East Asian populations.

The Mechanism

Arginine-456 sits in a structurally critical region of the CYP1A2 protein. The substitution to histidine disrupts the tertiary folding required for heme incorporation — the spectral peak at 450 nm that defines an active cytochrome P450 enzyme is barely detectable in cells expressing the *8 variant. Without the iron-containing heme cofactor properly seated, the enzyme cannot perform the oxygen-insertion reactions that metabolize drugs and other substrates.

Saito et al. (2005)22 Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 expressed the *8 variant in Chinese hamster V79 cells and a baculovirus system, measuring its activity against [7-ethoxyresorufin | A standard CYP1A2 probe substrate used to assess oxidative activity in vitro] and phenacetin. The variant retained approximately 30% of wild-type protein expression but showed less than 3% of wild-type maximum velocity (Vmax), and less than 1% of the catalytic efficiency (Vmax/Km) — effectively a non-functional enzyme despite being present in the cell.

The Evidence

The functional characterisation by Saito et al. (2005)33 Saito et al. (2005)
Saito Y et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos, 2005 established CYP1A2*8 as a severe loss-of-function allele in vitro, with catalytic efficiency less than 1% of wild-type. This places it among the most functionally damaging CYP1A2 variants identified.

Population data from the 38KJPN Japanese genome project records the A allele at approximately 0.65% frequency (501/77,444 alleles), compared with near-zero frequency in European and African cohorts. The global TopMed frequency is ~0.005% (1 in 20,000 alleles). This extreme population stratification means the clinical relevance of *8 is almost entirely concentrated in East Asian individuals.

Because individuals carrying two *8 alleles (AA homozygotes) are expected to be vanishingly rare even in Japanese populations, the most clinically actionable scenario is a heterozygous carrier (AG) who also carries a second non-functional or reduced-function CYP1A2 allele — creating a compound heterozygous [poor metabolizer | Poor metabolizer (PM): both copies of the gene carry loss-of-function alleles, leaving the individual with minimal enzyme activity] state.

Practical Actions

CYP1A2 poor metabolizers have substantially reduced clearance of caffeine, theophylline, and certain psychiatric medications. The most clinically significant implications are:

Theophylline: a narrow therapeutic index bronchodilator where twofold differences in clearance can shift a patient from sub-therapeutic to toxic plasma levels. Poor metabolizers require lower doses and close plasma-level monitoring.

Clozapine and olanzapine: both antipsychotics are primarily cleared by CYP1A2. Poor metabolizers can accumulate several-fold higher plasma concentrations at standard doses, increasing the risk of sedation, QTc prolongation, and other dose-dependent adverse effects.

Caffeine: while not a medication safety issue for most people, the near-complete loss of CYP1A2 activity means caffeine is cleared extremely slowly, amplifying both its stimulant effects and its potential to disrupt sleep.

Carcinogen bioactivation: CYP1A2 activates [heterocyclic amines | Compounds formed in grilled and charred meats (e.g. PhIP, IQ) that require CYP1A2 activation to become DNA-damaging carcinogens] from grilled and charred meat into DNA-damaging intermediates. Reduced CYP1A2 activity in *8 carriers may alter their net carcinogen exposure from dietary sources, though the direction of effect depends on competing detoxification pathways.

Interactions

CYP1A2 activity is powerfully modified by environmental factors — tobacco smoke and cruciferous vegetables induce CYP1A2, while fluvoxamine, ciprofloxacin, and omeprazole inhibit it. These interactions act on top of the genetic baseline. A *8 carrier who also smokes will still have minimal enzyme activity because the structural basis for inducibility is eliminated by the missense change.

The common CYP1A2 regulatory variant rs762551 (*1F) acts through a completely different mechanism — inducibility — and does not compensate for the structural loss of function caused by *8. Carriers of both rs762551 C and rs72547517 A would have reduced inducibility compounded by structural loss of function on the *8 chromosome.

Drug Interactions

caffeine increased_toxicity literature
theophylline increased_toxicity DPWG
clozapine increased_toxicity literature
olanzapine increased_toxicity literature
melatonin increased_toxicity literature
tizanidine increased_toxicity FDA
tacrine increased_toxicity literature

Nutrient Interactions

caffeine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal Metabolizer Normal

Wild-type — no CYP1A2*8 variant detected

You carry two copies of the reference (G) allele at rs72547517. You do not carry the CYP1A2*8 allele. This is the standard genotype, found in essentially all individuals of European and African ancestry and the vast majority (~99%) of East Asian individuals.

Your CYP1A2 enzyme structure is unaffected by this variant. Other CYP1A2 polymorphisms (such as rs762551, which affects inducibility) may still influence your caffeine and drug metabolism capacity.

AA CYP1A2*8 Poor Metabolizer Poor

Homozygous CYP1A2*8 — near-complete loss of CYP1A2 enzyme activity

CYP1A2*8 (Arg456His) prevents proper heme cofactor incorporation into the CYP1A2 enzyme. In vitro, cells expressing two *8 alleles would produce protein that cannot perform oxidative metabolism. The functional characterisation by Saito et al. (2005) [PMID 16174806] established Vmax at <3% and Vmax/Km at <1% of wild-type — effectively classifying this as a null or near-null allele.

Clinically, a CYP1A2 poor metabolizer encounters dramatically reduced clearance for every major CYP1A2 substrate. For theophylline, normal half-life is approximately 8 hours; in CYP1A2 poor metabolizers, accumulation to toxic levels can occur rapidly at standard doses. For clozapine and olanzapine, plasma concentrations may reach two- to four-fold higher than expected, with corresponding increases in sedation, hypersalivation, seizure risk (clozapine), and QTc prolongation.

Caffeine, which most people metabolise with a half-life of 3-5 hours, can accumulate significantly — triggering persistent tachycardia, anxiety, and severe sleep disruption at amounts that a normal metabolizer would clear within a few hours.

AG CYP1A2*8 Carrier Carrier

Carrier of one CYP1A2*8 allele — reduced enzyme activity on one chromosome

The CYP1A2*8 allele produces a protein with approximately 30% of normal expression and less than 3% of wild-type maximum velocity (Vmax) for standard substrates [Saito et al. 2005, PMID 16174806]. The near-complete loss of activity is due to impaired heme incorporation — the spectroscopic signature of an active CYP450 (the 450 nm peak) is barely detectable in cells expressing the *8 protein.

As a heterozygous AG carrier, your CYP1A2 output comes primarily from the normal G allele chromosome. In the absence of other CYP1A2 function-reducing variants, you are likely an intermediate metabolizer — faster than a homozygous *8 individual, but potentially slower than someone with two fully functional alleles.

The clinical significance is amplified when CYP1A2 substrates with narrow therapeutic indices are prescribed. Theophylline is the classic example: a reduction in clearance from one non-functional allele can shift plasma concentrations into the toxic range at standard dosing.